Comparative Effectiveness of Pyruvate Kinase M2 in Bile, Serum Carbohydrate Antigen 19-9, and Biliary Brushings in Diagnosing Malignant Biliary Strictures

Digestive Diseases and Sciences

Volumn 60, Issue 4, 2015, Pages 903-909

  Navaneethan, Udayakumar ^a   Lourdusamy, Vennisvasanth ^a   Poptic, Earl ^a   Hammel, Jeffrey P ^a   Sanaka, Madhusudhan R ^a   Parsi, Mansour A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bile; Brushings; Cholangiocarcinoma; Pancreatic cancer; Pyruvate kinase

Indexed keywords

CA 19-9 ANTIGEN; PYRUVATE KINASE;

ADULT; AGED; BILE; BILE DUCT; BILE DUCT CARCINOMA; BILIARY TRACT DISEASES; BLOOD; CHEMISTRY; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; MALE; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROSPECTIVE STUDY; STENOSIS, OCCLUSION AND OBSTRUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BILE; BILE DUCTS; BILIARY TRACT DISEASES; CA-19-9 ANTIGEN; CHOLANGIOCARCINOMA; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CONSTRICTION, PATHOLOGIC; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; PYRUVATE KINASE;

EID: 84934285769     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3397-7     Document Type: Article

References (29)

1. Victor DW, Sherman S, Karakan T, Khashab MA. Current endoscopic approach to indeterminate biliary strictures. World J Gastroenterol. 2012;18:6197–6205.
2. Parsi MA, Deepinder F, Lopez R, Stevens T, Dodig M, Zuccaro G. Factors affecting the yield of brush cytology for the diagnosis of pancreatic and biliary cancers. Pancreas. 2011;40:52–54.
3. Ponchon T, Gagnon P, Berger F, et al. Value of endobiliary brush cytology and biopsies for the diagnosis of malignant bile duct stenosis: results of a prospective study. Gastrointest Endosc. 1995;42:565–572.
4. Baron TH, Harewood GC, Rumalla A, et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol. 2004;2:214–219.
5. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–1617.
6. Marrelli D, Caruso S, Pedrazzani C, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009;198:333–339.
7. Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol. 2011;9:434e1–439e1.
8. Bonney GK, Craven RA, Prasad R, Melcher AF, Selby PJ, Banks RE. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol. 2008;9:149–158.
9. Venkatesh PG, Navaneethan U, Shen B, McCullough AJ. Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci. 2013;58:850–857. doi:10.1007/s10620-012-2401-3.
10. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350–355.
11. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266–270.
12. Navaneethan U, Gutierrez NG, Jegadeesan R, et al. Vascular endothelial growth factor levels in bile distinguishes pancreatic cancer from other etiologies of biliary stricture: a pilot study. Dig Dis Sci. 2013;58:2986–2992. doi:10.1007/s10620-013-2764-0.
13. Navaneethan U, Gutierrez NG, Venkatesh PG, et al. Lipidomic profile of bile in distinguishing benign and malignant biliary strictures-A single blinded pilot study. Am J Gastroenterol. 2014: (Epub ahead of print). doi: 10.1038/ajg.2014.60.
14. Navaneethan U, Parsi MA, Gutierrez NG, et al. Volatile organic compounds can diagnose pancreatic cancer as the etiology of malignant biliary strictures -A preliminary observation. Gastrointest Endosc. 2014: (Epub ahead of print). doi: 10.1016/j.gie.2014.04.016.
15. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15:300–308.
16. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growth. Nature. 2008;452:230–233. doi:10.1038/nature06734.
17. Cerwenka H, Aigner R, Bacher H, et al. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res. 1999;19:849–851.
18. Kumar Y, Gurusamy K, Pamecha V, Davidson BR. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis. Pancreas. 2007;35:114–119.
19. Novotny I, Dite P, Dastych M, et al. Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer. Hepatogastroenterology. 2008;55:1475–1477.
20. Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci. 2004;49:1149–1155.
21. Kumar Y, Tapuria N, Kirmani N, Davidson BR. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol. 2007;19:265–276.
22. Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer. 2005;117:825–830.
23. Dhar DK, Olde Damink SW, Brindley JH, et al. Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer. Cancer. 2013;119:575–585. doi:10.1002/cncr.27611.
24. Stevens T. Role of endoscopic ultrasonography in the diagnosis of acute and chronic pancreatitis. Gastrointest Endosc Clin N Am. 2013;23:735–747.
25. Joergensen MT, Schaffalitzky de Muckadell OB, Heegaard NH. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer. Pancreas. 2010;39:243–247.
26. Li YG, Zhang N. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma. Dig Liver Dis. 2009;41:605–608.
27. Navaneethan U, Singh T, Gutierrez NG, Jegadeesan R, Gk Venkatesh P, Brainard J, Vargo JJ, Parsi MA. Predictors for detection of cancer in patients with indeterminate biliary stricture and atypical cells on endoscopic retrograde brush cytology. J Dig Dis. 2014: (Epub ahead of print). doi: 10.1111/1751-2980.12134.
28. Parsi MA, Li A, Li CP, et al. DNA methylation alterations in endoscopic retrograde cholangiopancreatography brush samples of patients with suspected pancreaticobiliary disease. Clin Gastroenterol Hepatol. 2008;6:1270–1278.
29. Navaneethan U, Njei B, Venkatesh PG, Vargo JJ, Parsi MA. Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc. 2013. (Epub ahead of print). doi: 10.1016/j.gie.2013.11.001.